Clinical and molecular profiling of AML patients with chromosome 7 or 7q deletions in the context of
AML
Myeloid leukemias and dysplasias
TP53
chr7 del
chr7q del
venetoclax
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
pubmed:
13
9
2022
medline:
21
12
2022
entrez:
12
9
2022
Statut:
ppublish
Résumé
Deletions in chromosome 7 (del(7)) or its long arm (del(7q)) constitute the most common adverse cytogenetic events in acute myeloid leukemia (AML). We retrospectively analyzed 243 treatment-naive patients with AML and del(7) (168/243; 69%) or del(7q) (75/243; 31%) who did not receive any myeloid-directed therapy prior to AML diagnosis. This is the largest comprehensive clinical and molecular analysis of AML patients with del(7) and del(7q). Our results show that relapse-free survival was significantly longer for AML patients with del(7q) compared to del(7), but the overall survival and remission duration were similar. TP53 mutations and del5/5q were the most frequent co-occurring mutations and cytogenetic abnormalities, and conferred worse outcomes in del(7) and del(7q) patients. Venetoclax-based treatments were associated with worse outcomes in TP53 mutated AML patients with del(7) or del(7q), as well as del(7) with TP53 wildtype status, requiring further investigation.
Identifiants
pubmed: 36089905
doi: 10.1080/10428194.2022.2118533
pmc: PMC9772202
mid: NIHMS1848328
doi:
Substances chimiques
venetoclax
N54AIC43PW
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
3105-3116Subventions
Organisme : NCI NIH HHS
ID : F32 CA271697
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R03 CA270725
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009666
Pays : United States
Références
Haematologica. 2014 Mar;99(3):465-73
pubmed: 24142997
Lancet. 1973 Dec 8;2(7841):1326-7
pubmed: 4127670
Nat Rev Clin Oncol. 2020 Oct;17(10):592
pubmed: 32820266
Leukemia. 1988 Jul;2(7):403-12
pubmed: 3164797
Blood. 2010 Jul 22;116(3):354-65
pubmed: 20385793
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Cancer. 2021 Oct 15;127(20):3772-3781
pubmed: 34255353
Blood. 2012 Mar 1;119(9):2114-21
pubmed: 22186996
Blood Adv. 2021 May 25;5(10):2481-2489
pubmed: 34003250
N Engl J Med. 2020 Aug 13;383(7):617-629
pubmed: 32786187
Am J Hematol. 2019 Feb;94(2):231-239
pubmed: 30456896
J Clin Oncol. 2004 Aug 15;22(16):3432-3
pubmed: 15310791
J Egypt Natl Canc Inst. 2018 Dec;30(4):133-138
pubmed: 30472199
Lancet. 1973 Dec 15;2(7842):1385-6
pubmed: 4128073
Cold Spring Harb Perspect Biol. 2010 Jun;2(6):a000919
pubmed: 20516128
Br J Haematol. 2014 Aug;166(4):550-6
pubmed: 24931631
Blood. 2003 Jul 1;102(1):43-52
pubmed: 12623843
Am J Hematol. 2012 Jul;87(7):684-6
pubmed: 22565657
Genes Chromosomes Cancer. 2019 Oct;58(10):698-704
pubmed: 30994218
Blood Adv. 2020 May 12;4(9):1942-1949
pubmed: 32380535
Blood. 1998 Oct 1;92(7):2322-33
pubmed: 9746770
J Clin Oncol. 1990 Jan;8(1):75-83
pubmed: 2295913